B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542

Benzinga Newsdesk www.benzinga.com Negative 60.9%

Neg 60.9% Neu 0% Pos 0%

B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.